+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Europe Postpartum Depression Drugs Market Size, Share & Trends Analysis Report By Treatment (Pharmacotherapy, Hormonal Therapy, and Others), By Route of Administration, By Distribution Channel, By Type, By Country and Growth Forecast, 2024 - 2031

  • PDF Icon

    Report

  • 141 Pages
  • August 2024
  • Region: Europe
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5992336
The Europe Postpartum Depression Drugs Market would witness market growth of 9.2% CAGR during the forecast period (2024-2031).

The Germany market dominated the Europe Postpartum Depression Drugs Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $106.8 million by 2031. The UK market is exhibiting a CAGR of 8.3% during (2024 - 2031). Additionally, The France market would experience a CAGR of 10.1% during (2024 - 2031).



Postpartum depression drugs are also effective in managing symptoms of anxiety that often accompany postpartum depression. These symptoms may include excessive worry, restlessness, irritability, and physical manifestations such as palpitations or muscle tension. Antidepressants with anxiolytic properties, such as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), are commonly prescribed to address both depressive and anxiety symptoms.

In some cases, these drugs may be used preventatively for women at high risk of developing PPD. Factors that may increase the risk include a history of depression or anxiety, hormonal fluctuations, stressful life events, or inadequate social support. Starting medication early, especially for women with a history of PPD, can help mitigate the onset or severity of symptoms.

The expansion of telemedicine in Italy enhances access to mental health services, including consultations for postpartum depression. Remote consultations and digital platforms facilitate easier access for patients in remote or underserved areas, increasing awareness and treatment-seeking behaviors. Also, increased investment in healthcare stimulates research and development initiatives focused on advancing postpartum depression drugs. Collaborations between Italian pharmaceutical companies and research institutions lead to the innovation of new treatment options tailored to local patient needs. Hence, the increasing healthcare sector is driving the market's growth.

Based on Treatment, the market is segmented into Pharmacotherapy, Hormonal Therapy, and Others. Based on Route of Administration, the market is segmented into Oral, Parenteral, and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Based on Type, the market is segmented into Postpartum Anxiety, Postpartum Blues, Postpartum Obsessive-Compulsive Disorder (OCD), Postpartum Panic Disorder, Postpartum Post-Traumatic Stress Disorder (PTSD), and Postpartum Psychosis. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

List of Key Companies Profiled

  • Pfizer, Inc.
  • Eli Lilly And Company
  • Novartis AG
  • GlaxoSmithKline PLC (GSK)
  • Merck & Co., Inc.
  • Biogen, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Bausch Health Companies, Inc.(DermTech, Inc.)
  • Cipla Limited
  • Sage Therapeutics, Inc.

Market Report Segmentation

By Treatment
  • Pharmacotherapy
  • Hormonal Therapy
  • Others
By Route of Administration
  • Oral
  • Parenteral
  • Others
By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
By Type
  • Postpartum Anxiety
  • Postpartum Blues
  • Postpartum Obsessive-Compulsive Disorder (OCD)
  • Postpartum Panic Disorder
  • Postpartum Post-Traumatic Stress Disorder (PTSD)
  • Postpartum Psychosis
By Country
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Postpartum Depression Drugs Market, by Treatment
1.4.2 Europe Postpartum Depression Drugs Market, by Route of Administration
1.4.3 Europe Postpartum Depression Drugs Market, by Distribution Channel
1.4.4 Europe Postpartum Depression Drugs Market, by Type
1.4.5 Europe Postpartum Depression Drugs Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
3.3 Porter Five Forces Analysis
Chapter 4. Europe Postpartum Depression Drugs Market by Treatment
4.1 Europe Pharmacotherapy Market by Country
4.2 Europe Hormonal Therapy Market by Country
4.3 Europe Others Market by Country
Chapter 5. Europe Postpartum Depression Drugs Market by Route of Administration
5.1 Europe Oral Market by Country
5.2 Europe Parenteral Market by Country
5.3 Europe Others Market by Country
Chapter 6. Europe Postpartum Depression Drugs Market by Distribution Channel
6.1 Europe Hospital Pharmacy Market by Country
6.2 Europe Retail Pharmacy Market by Country
6.3 Europe Online Pharmacy Market by Country
Chapter 7. Europe Postpartum Depression Drugs Market by Type
7.1 Europe Postpartum Anxiety Market by Country
7.2 Europe Postpartum Blues Market by Country
7.3 Europe Postpartum Obsessive-Compulsive Disorder (OCD) Market by Country
7.4 Europe Postpartum Panic Disorder Market by Country
7.5 Europe Postpartum Post-Traumatic Stress Disorder (PTSD) Market by Country
7.6 Europe Postpartum Psychosis Market by Country
Chapter 8. Europe Postpartum Depression Drugs Market by Country
8.1 Germany Postpartum Depression Drugs Market
8.1.1 Germany Postpartum Depression Drugs Market by Treatment
8.1.2 Germany Postpartum Depression Drugs Market by Route of Administration
8.1.3 Germany Postpartum Depression Drugs Market by Distribution Channel
8.1.4 Germany Postpartum Depression Drugs Market by Type
8.2 UK Postpartum Depression Drugs Market
8.2.1 UK Postpartum Depression Drugs Market by Treatment
8.2.2 UK Postpartum Depression Drugs Market by Route of Administration
8.2.3 UK Postpartum Depression Drugs Market by Distribution Channel
8.2.4 UK Postpartum Depression Drugs Market by Type
8.3 France Postpartum Depression Drugs Market
8.3.1 France Postpartum Depression Drugs Market by Treatment
8.3.2 France Postpartum Depression Drugs Market by Route of Administration
8.3.3 France Postpartum Depression Drugs Market by Distribution Channel
8.3.4 France Postpartum Depression Drugs Market by Type
8.4 Russia Postpartum Depression Drugs Market
8.4.1 Russia Postpartum Depression Drugs Market by Treatment
8.4.2 Russia Postpartum Depression Drugs Market by Route of Administration
8.4.3 Russia Postpartum Depression Drugs Market by Distribution Channel
8.4.4 Russia Postpartum Depression Drugs Market by Type
8.5 Spain Postpartum Depression Drugs Market
8.5.1 Spain Postpartum Depression Drugs Market by Treatment
8.5.2 Spain Postpartum Depression Drugs Market by Route of Administration
8.5.3 Spain Postpartum Depression Drugs Market by Distribution Channel
8.5.4 Spain Postpartum Depression Drugs Market by Type
8.6 Italy Postpartum Depression Drugs Market
8.6.1 Italy Postpartum Depression Drugs Market by Treatment
8.6.2 Italy Postpartum Depression Drugs Market by Route of Administration
8.6.3 Italy Postpartum Depression Drugs Market by Distribution Channel
8.6.4 Italy Postpartum Depression Drugs Market by Type
8.7 Rest of Europe Postpartum Depression Drugs Market
8.7.1 Rest of Europe Postpartum Depression Drugs Market by Treatment
8.7.2 Rest of Europe Postpartum Depression Drugs Market by Route of Administration
8.7.3 Rest of Europe Postpartum Depression Drugs Market by Distribution Channel
8.7.4 Rest of Europe Postpartum Depression Drugs Market by Type
Chapter 9. Company Profiles
9.1 Pfizer, Inc.
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Regional & Segmental Analysis
9.1.4 Research & Development Expense
9.1.5 SWOT Analysis
9.2 Eli Lilly And Company
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Regional Analysis
9.2.4 Research & Development Expenses
9.2.5 SWOT Analysis
9.3 Novartis AG
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental and Regional Analysis
9.3.4 Research & Development Expense
9.3.5 SWOT Analysis
9.4 GlaxoSmithKline PLC (GSK)
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Regional Analysis
9.4.4 Research & Development Expense
9.4.5 SWOT Analysis
9.5 Merck & Co., Inc.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expenses
9.5.5 SWOT Analysis
9.6 Biogen, Inc.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Regional Analysis
9.6.4 Research & Development Expense
9.6.5 Recent strategies and developments:
9.6.5.1 Trails and Approvals:
9.6.6 SWOT Analysis
9.7 Teva Pharmaceutical Industries Ltd.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Regional Analysis
9.7.4 Research & Development Expenses
9.7.5 SWOT Analysis
9.8 Bausch Health Companies, Inc. (DermTech, Inc.)
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental and Regional Analysis
9.8.4 Research & Development Expense
9.8.5 SWOT Analysis
9.9 Cipla Limited
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Segmental and Regional Analysis
9.9.4 Research & Development Expense
9.9.5 SWOT Analysis
9.10. Sage Therapeutics, Inc.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Research & Development Expenses

Companies Mentioned

  • Pfizer, Inc.
  • Eli Lilly And Company
  • Novartis AG
  • GlaxoSmithKline PLC (GSK)
  • Merck & Co., Inc.
  • Biogen, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Bausch Health Companies, Inc.(DermTech, Inc.)
  • Cipla Limited
  • Sage Therapeutics, Inc.

Methodology

Loading
LOADING...